CVSC Cardiovascular Sciences Inc (CE)

ORLANDO, FL announced that the Company is pleased to announce the appointment of John Martin of Virginia Beach, VA to its board of directors. Mr. Martin has extensive corporate experience including as the founder and president of Weight Loss Forever International, Inc., a franchise operation with some two dozen locations in the southeast. As the founder and president of that company, Mr. Martin helped formulate a line of natural herb supplements that proved effective in the Weight Loss Forever program. Mr. Martin also oversaw the corporate sites, addressed compliance of the franchise sites and was responsible for all corporate governance. He nurtured the company from its inception to a mature and very successful organization.

Dr. Larry Hooper, a physician and the CEO of Cardiovascular Sciences, Inc., announced, "We are so pleased to have John on board. His knowledge in the corporate world and his leadership abilities promise to be an excellent and complementary fit with the leadership of our company." He goes on to add, "John's knowledge and skills will allow us to explore other, possibly synergistic endeavors that will help speed our core technology toward the market."

Cardiovascular Sciences, Inc., a member of the award winning University of Central Florida Technology Incubator, has offices in the Research Park adjacent to the UCF campus. The company has developed, with Dr. Kevin Belfield, a technology that promises to bring a much needed solution to the $6+ billion global market dealing with post-surgical adhesions and their complications. During many surgeries, stressed tissues can adhere to each other, creating a scar that can cause complications from mild discomfort to significant disability to life threatening obstruction. The company's second generation material is currently going into expanded animal trials and further development to widen the range of applications in which it will be useful.

About Cardiovascular Sciences

Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals.

The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well.

In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development. www.cvsciences.org

Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.

For more information contact: Cardiovascular Sciences Investor Relations 800-858-7502 ir@cvsciences.org

Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
Von Mär 2025 bis Apr 2025

Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
Von Apr 2024 bis Apr 2025